H. Depenbrock

发表

Effects of the microtubule-disturbing agents docetaxel (Taxotere), vinblastine and vincristine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitro.

A. Hanauske, H. Depenbrock, D. Shirvani, 1994, European journal of cancer.

Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study

M. Ahn, Keunchil Park, S. Thongprasert, 2017, Cancer research and treatment : official journal of Korean Cancer Association.

Phase-I-study of four different schedules of pemetrexed, gemcitabine and cisplatin in patients with locally advanced or metastatic solid tumours.

A. Hanauske, U. Ohnmacht, H. Depenbrock, 2008, European journal of cancer.

A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).

C. Schumann, M. Socinski, F. Hirsch, 2014 .

Efficacy of 5′-nor-anhydrovinblastine (vinorelbine), against freshly explanted clonogenic human tumor cells in vitro

A. Hanauske, T. Block, H. Depenbrock, 2004, Investigational New Drugs.

Effects of cytokines on in vitro colony formation of primary human tumour specimens.

G. Erdmann, M. Freund, W. D. de Riese, 1990, European journal of cancer.

In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells.

J. Jimeno, G. Faircloth, A. Hanauske, 1998, British Journal of Cancer.

Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents.

C. Fellbaum, M. Aapro, H. Nekarda, 1993, European journal of cancer.

Preclinical activity of trans-indazolium[tetrachlorobisindazoleruthenate(III)] (NSC 666158; IndCR; KP 1019) against tumour colony-forming units and haematopoietic progenitor cells.

B. Keppler, G. Weirich, A. Hanauske, 1997, European journal of cancer.

In vitro activity of liposomal N4octadecyl-1-β-D-arabinofurano-sylcytosine (NOAC), a new lipophilic derivative of 1-β-D-arabino-furanocylcytosine on biopsized clonogenic human tumor cells and hematopoietic precursor cells

R. Schwendener, H. Schott, A. Hanauske, 2004, Investigational New Drugs.

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.

C. Schumann, M. Socinski, R. Kurek, 2015, The Lancet. Oncology.

Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin.

A. V. van Oosterom, R. Johnson, H. Dumez, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

C. Schumann, M. Socinski, R. Kurek, 2015, The Lancet. Oncology.

An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.

C. Obasaju, R. Ramlau, Joo‐Hang Kim, 2017, Clinical lung cancer.

Activity of NK 611, a new epipodophyllotoxin derivative, against colony forming units from freshly explanted human tumours in vitro.

A. Hanauske, M. Rotter, H. Depenbrock, 1995, European journal of cancer.

Interleukin 1 modulates growth of human renal carcinoma cells in vitro.

A. Hanauske, H. Depenbrock, J. Rastetter, 1995, British Journal of Cancer.

Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE)

C. Kropf-Sanchen, M. Socinski, Michael Thomas, 2016, Oncology Research and Treatment.

Effects of vinorelbine on epidermal growth factor-receptor binding of human breast cancer cell linesin vitro

J. Rastetter, A. Shirvani, A. Hanauske, 2004, Investigational New Drugs.

Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non–Small‐Cell Lung Cancer

C. Obasaju, M. Socinski, R. Ramlau, 2017, Clinical lung cancer.

Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial.

F. Lordick, V. Heinemann, C. Köhne, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Preliminary results of a phase I study with MTA (LY231514) in combination with cisplatin in patients with solid tumors.

R. Johnson, A. Hanauske, R. Thödtmann, 1999, Seminars in Oncology.

Gemcitabine and etoposide in small cell lung cancer: phase I and II trials.

U. Gatzemeier, A. Hanauske, R. Thödtmann, 1997, Seminars in Oncology.

C. Schumann, M. Socinski, R. Kurek, 2015, The Lancet. Oncology.

A phase I study of MTA (multi-targeted antifolate, LY231514) plus cisplatin (CIS) in patients with advanced solid tumours

A. Hanauske, J. Blatter, U. Ohnmacht, 1997 .

Growth Factor-Dependent Stimulation of Primary Human Tumor Cells

M. Freund, H. Meyer, A. Hanauske, 1990 .

C. Kropf-Sanchen, M. Socinski, Michael Thomas, 2016, Oncology Research and Treatment.